Systemically Infused Mesenchymal Stem Cells Show Different Homing Profiles in Healthy and Tumor Mouse Models

CHENGYING XIE,a ZHANGRU YANG,a YUANZHEN SUO,a QIANQIAN CHEN,a DAN WEI,a XIAOFU WENG,a ZHENGQIN GU,b XUNBIN WEIA

Key Words. Mesenchymal stem cells • Homing • Hepatocellular carcinoma • Tumor xenograft model • In vivo flow cytometry

ABSTRACT

Bone marrow-derived mesenchymal stem cells (MSCs) can localize in injured, inflamed, and cancerous tissues after systemic infusion. However, the dynamic homing profile of MSCs in the peripheral blood is not well characterized. Here, using in vivo flow cytometry to noninvasively monitor the dynamics of fluorescence-labeled cells, we found different clearance kinetics of systemically infused MSCs between healthy and tumor mouse models. The circulation times of MSCs in healthy mice and mice with subcutaneous tumors, orthotopically transplanted liver tumors, or metastatic lung tumors were 30, 24, 18, and 12 hours, respectively, suggesting that MSCs actively home to tumor environments. MSCs infiltrated into hepatocellular carcinoma (HCC) sites and preferentially engrafted to micrometastatic regions both in vivo and in vitro. The expression of epidermal growth factor, CXCL9, CCL25, and matrix metalloproteinases-9 by HCC cells differed between primary tumor sites and metastatic regions. By characterizing the homing profiles of systemically perfused MSCs under physiological and cancerous conditions, these findings increase our understanding of the migration of MSCs from the circulation to tumor sites and constitute a basis for developing MSC-based anti-cancer therapeutic strategies.

SIGNIFICANCE STATEMENT

Bone marrow mesenchymal stem cells (MSCs) are a rare population of nonhematopoietic stromal cells with tropism to damaged or tumor sites. However, the dynamic homing profile of systemically infused MSCs in vivo is not illustrated. Here, we have observed that MSCs possess different circulation times between healthy and tumor mouse models. After depleted from blood stream, MSCs migrate to periphery of tumor regions and preferentially infiltrate into micrometastasis both in vivo and in vitro. The expression of cytokine epidermal growth factor, CXCL9, CCL25, and MMP9 were differently expressed between primary tumor and metastasis sites, especially when cocultured with MSCs, suggesting a crosstalk between MSCs and tumor cells. These results first present the dynamic homing profile of MSCs in periphery blood under physiological and tumor conditions. It helps us understand the homing mechanism of systemically administered MSCs, and design MSCs-based vehicles to deliver therapeutic agents for targeted tumor therapy.

INTRODUCTION

Hepatocellular carcinoma (HCC) ranks fifth worldwide among all malignancies and is the third leading cause of cancer mortality [1]. Tumors are often considered “wounds that never heal” [2], consisting of both cancer cells and diverse cells of origin from different tissue and organs that facilitate a microenvironment conducive to carcinogenesis [3]. Tumor microenvironments mainly include angiogenic vascular cells, infiltrating immune cells, and cancer-associated fibroblastic cells [4]. Cancer-associated fibroblastic cells may arise from fibroblasts residing in local tissues and periadventitial cells including pericytes, vascular smooth muscle cells, endothelial cells, and bone marrow-derived cells including various stem cells [5]. Mesenchymal stem cells (MSCs) are nonhematopoietic multipotent stem cells that can be isolated from various tissues such as bone marrow, adipose tissue, fetal lung tissue, placental tissue, and umbilical cord blood [6]. Recently, several studies suggest that MSCs are recruited by neoplasia as a potential source of cancer-
associated fibroblastic cells to create a favorite niche that promotes carcinogenic progression by paracrine secretion to increase metastatic abilities [7,8], recruit and activate infiltrating immune cells to provide mitogenic signals to cancer cells [5], stimulate angiogenesis or remodel neovascularization [9], and promote tumor growth [4]. Systemically infused MSCs localize within injured, inflamed, and cancerous tissues, suggesting that MSCs could serve as a cellular drug delivery system for multiple applications. MSCs have been genetically engineered to express specific cytokines to treat cancer due to their innate tropism for tumor environments [10–13]. However, the efficiency and speed with which systemically infused MSC traffic to specific sites is unclear. Furthermore, the mechanisms underlying the homing process and recruitment of MSCs into tumors and their potential role in malignant tumor progression are not well known.

There are three main approaches to detecting MSCs after intravenous infusion: (a) ex vivo histological analysis including tissue sectioning, species mismatch [14], real-time polymerase chain reaction (RT-PCR) [15], and live tissue imaging [16]; (b) imaging methods to visualize cell homing in different organs, including bioluminescence imaging [17], single-photon emission computed tomography, nuclear scintigraphic tracking [18], positron emission tomography, intravital microscopy [14], and magnetic resonance imaging [19]; and (c) quantification of MSCs in peripheral blood by conventional ex vivo flow cytometry [16]. Each approach has advantages and disadvantages. For instance, histological analysis requires sacrificing many animals at multiple time points, and sampling is limited when only certain parts of the tissue or organ are harvested and analyzed. Positron emission tomography and nuclear scintigraphic tracking require radioisotope tagging to quantify the relative level of radioactivity in excised tissues and organs within a short period of time. Tracking cells by magnetic resonance imaging requires labeling with contrast agents to visualize the cells, and false positives are observed even if the grafted cells die. Also, using conventional ex vivo flow cytometry to detect MSCs in the circulation requires frequent blood sampling and short testing windows.

However, in vivo flow cytometry can be used to quantify fluorescence-labeled cells in the circulation without extracting blood samples, allowing noninvasive and continuous assessment of larger blood volumes than ex vivo flow cytometry [20]. This technique has been used to detect and quantify rare circulating cells in vivo, such as circulating tumor cells [21,22], hematopoietic stem cells [23], lymphocytes [24], and apoptotic cells [25].

Here, we monitored MSCs transfected with green fluorescent protein (GFP) by in vivo flow cytometry to study the homing time course and fate of MSCs after systemic delivery into healthy mice and three types of malignant HCC mouse models. We found that the homing profiles of MSCs in the peripheral blood differed between healthy mice and HCC tumor mouse models and that MSCs preferentially homed to micro metastatic regions over primary tumor sites. Moreover, our results suggest that MSCs display different patterns of responses to paracrine factors secreted by HCC cells in primary tumor sites and metastatic regions both in vitro and in vivo.

### MATERIALS AND METHODS

**Animals**

Animal care and experimental protocols were in accordance with guidelines established by the Shanghai Medical Experimental Animal Care Commission. Balb/c nude mice (male, 6 weeks old, 20 ± 2 g) were purchased from Shanghai Laboratory Animal Center. All procedures were approved by the Ethical Committee of Animal Experiments of Med-X Research Institute and the School of Biomedical Engineering at Shanghai Jiao Tong University.

**Isolation and Expansion of MSCs**

Balb/c mice (2–3 weeks old) were decapitated, and the femur and tibia were carefully removed. Bone marrow cells were flushed with a syringe (27-gauge) inserted into one end of the bone and cultured at a density of 3 × 10^5 cells/cm^2 with low-glucose Dulbecco’s modified Eagle’s medium (DMEM; Gibco) containing 15% fetal bovine serum (FBS; Gibco) and 1% penicillin/streptomycin (Gibco). After 2 hours, nonadherent cells were removed via medium changes, which were repeated every 3 days until the cultured cells reached 70%–80% confluence. Cells were then digested with TrypLE Express (Gibco) for 2 minutes and passaged. All experiments used MSCs at passage 5–8.

To evaluate their multipotent differentiation potential, MSCs were incubated at passage 5 in a 12-well plate at a density of 5 × 10^3 cells/cm^2 with osteogenesis differentiation medium (Gibco) or at a density of 1 × 10^5 cells/cm^2 with an adipogenesis differentiation kit (Gibco) for 3 weeks. According to the manufacturer’s instructions, other MSCs were seeded at a higher density of 1 × 10^4 cells per milliliter to formulate a micromass and cultured with a STEMPRO chondrogenesis differentiation kit (Gibco) with medium changes every 3 days for 2 weeks. Osteoblasts were stained using Alizarin Red S (Sigma), adipocytes were stained with Oil Red O (Sigma), and chondrogenesis pellets were stained with Toluidine Blue (Sigma).

**Conventional Ex Vivo Flow Cytometry**

MSCs were trypsinized and resuspended at a density of 1 × 10^5 cells in 100 µl cold PBS and stained with 1 µg antibody against CD29, CD44, stem cell antigen (Sca-1), CD45, CD34, or CD31 (eBioscience, San Diego) at 4°C for 40 minutes. After fixation in dark conditions, MSCs were analyzed by a flow cytometer (FACS Aria II, Becton, Dickinson and Company, Franklin Lakes, NJ) to identify cell surface markers and purity. To evaluate the sensitivity and accuracy of the data obtained from in vivo flow cytometry, blood samples were analyzed by BD FACSCalibur and FlowJo 7.0 software (Becton, Dickinson and Company). After MSC infusion through the tail vein, 150 µl blood samples were collected through the orbital venous plexus of mice at different time points.

**Cell Culture and Transfection Procedure**

A human HCC cell line, HCCLM3, with high metastatic potential was established at the Liver Cancer Institute, Zhongshan Hospital, Fudan University [26] and maintained in high-glucose DMEM with 10% FBS. HCCLM3 cells were transfected with linearized pTurboRFP (Evrogen) or pIREs-EGFP (Clontech) using Lipofectin2000 reagent (Invitrogen). Stable expression of red fluorescent protein (RFP) or GFP was achieved by selecting with 800 µg/ml neomycin. HepG2 and 293T cells were cultured in DMEM with 10% FBS. MSCs were transfected by adenoexpresses with pDOV-mCMV-MCS-EGFP (Obio Technology Co., Ltd.) at 5,000 viral particles per cell for 60 hours in cell culture medium. The transfection efficiency of MSCs was above 95% based on conventional ex vivo flow cytometry results.

www.StemCellsTM.com © 2017 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
Cell Migration Assay

The ability of MSCs to migrate to HCCLM3 cells was confirmed by in vitro cell migration assay. HCCLM3, HepG2, and 293T cells were seeded at a density of $2.5 \times 10^5$ cells in 800 µl culture medium in the bottom well of a transwell plate (8-µm pore size polycarbonate membrane, Becton, Dickinson) for 24 hours. Then, $4 \times 10^6$ MSCs in 300 µl culture medium were added to the top well. After coculture in an incubator for 24 hours, MSCs remaining on the top side of the membrane were removed by a cotton swab, and migrated cells on the bottom side were fixed. MSCs were stained with 0.5% crystal violet (Sigma-Aldrich). Twenty fields per well were randomly selected and counted at $\times 10$ magnification with a microscope (Leica). Data were analyzed by Image Pro Plus 6.0 software.

For coculture studies, $1 \times 10^7$ MSCs were seeded on the top of a 0.4-µm pore size 6-well transwell plate (Corning Costar, Cambridge, MA). GFP-HCCLM3 cells were seeded at a density of $5 \times 10^5$ cells on the bottom to prevent contact between tumor cells and MSCs. After incubation for 24 hours, total RNA was extracted from MSCs or GFP-HCCLM3 cells using Trizol reagent (Invitrogen).

Tumor Cell Extraction From Tissue and Culture

All isolation procedures were performed under aseptic conditions. Micrometastatic foci were isolated by microscopic forceps under a stereomicroscope and identified by a GFP + signal with a fluorescence microscope. Primary tumor tissues were obtained from the orthotopic transplantation region. After discarding non-fluorescent tissues, tumor tissues were cut into small pieces ($\sim 1$ mm$^3$) by microscissors. The tissue was then suspended in 3 ml DMEM containing 10% (vol/vol) FBS in the presence of 1 mg/ml (wt/vol) collagenase IV (Gibco) with 75 U/ml DNAase I (Sigma-Aldrich) in a 50-ml centrifuge tube and digested for 2 hours in a shaking incubator at 37°C at a shaking speed of 400 rpm. The cell suspension was then filtered through a 70-µm filter mesh to remove connective tissue, and cell clumps were digested with 0.25% trypsin for 5 minutes. Cultured medium was added to stop trypsin digestion, and the cell suspension was centrifuged at 1,200 rpm at 4°C for 5 minutes. The digestion medium was discarded, and the cells were seeded onto 60-mm culture dishes in 3 ml complete medium at 37°C in a 5% CO$_2$ incubator for 3 days. After 10 days of culture, the cells were harvested, and GFP + cells were isolated by fluorescence-activated cell sorting for further studies. We used cells at passage 2-3 for gene expression experiments and MSC coculture tests.

Xenograft Tumor Model and Administration of MSCs

For HCC tumor mouse models, $5 \times 10^6$ RFP-HCCLM3 cells in 100 µl PBS were injected under the armpit of nude mice ($n = 8$). We performed the tumor block transplantation method in a sterile environment as previously described [21]. Briefly, a tumor mass obtained from the subcutaneous implant region was cut into small cubes sized $\sim 1$ mm$^3$. Recipient mice ($n = 8$) were anesthetized with ketamine/xylazine (100 mg/10 mg per kg, Sigma-Aldrich, St. Louis, MO). The abdomen was disinfected with betadine scrub and 75% medical alcohol. After opening a small subcostal incision, the left lateral lobe of the liver margin was exposed and extracted. The tumor cube was then implanted through a tiny superficial incision of the liver. The incision was closed with a 7-0 suture to prevent early peritoneal dissemination of tumor cells. For metastatic lung tumor mouse models, RFP-HCCLM3 cells ($2 \times 10^6$) in 200 µl PBS were intravenously (i.v.) injected into the tail vein of nude mice and allowed to inoculate the lung ($n = 8$). After 4 weeks of tumor establishment, $1 \times 10^6$ GFP-MSCs were injected into the caudal vein and measured by in vivo flow cytometry.

In Vivo Flow Cytometry

To monitor the dynamics of GFP-MSCs in peripheral blood, we performed in vivo flow cytometry as described in a previous study [21]. Briefly, an artery about 50–70 µm from the left ear was selected using transillumination with a 535 ± 15 nm light-emitting diode to observe the vasoganglion. Light from a 488-nm laser was modulated to a narrow slit across the chosen artery. The beam size at the focal plane was approximately $5 \times 72$ µm. The depth of focus on the region of interest (i.e., the full width at half maximum of the light slit projected onto the sample in the axial direction) was approximately 50 µm. The passage of fluorescence-labeled cells through the focused laser slit produced a fluorescence signal that was detected with a photomultiplier tube and sampled at a rate of 5 kHz with a data acquisition card.

Immunohistochemistry and Immunofluorescence

To assess the recruitment of GFP-MSCs to the tumor region and other tissues, staining with specific markers was performed. The tissue samples were fixed in precooled isopentane and stored in a −80°C refrigerator. Frozen tissues were embedded with Optimal Cutting Temperature and sliced into 8-µm cryosections, which were then stained with rat anti-GFP and rabbit anti-RFP antibodies (Abcam, Cambridge, U.K.) followed by Alexa Fluor 488- or 594-labeled secondary antibodies. After rinsing three times in PBS, the sections were mounted with 4’,6-diamidino-2-phenylindole (H&E) solution and examined by microscopy.

RT-PCR

Total mRNA was obtained and transcribed to cDNA using the RevertAid First Stand cDNA Synthesis Kit (Thermoscientific, Lithuania) according to the manufacturer’s instructions. Quantitative RT-PCR was conducted with a SYBR Premix Ex Taq Kit (Takara) on an ABI 7900HT system (ABI, Foster, CA) with the following conditions: 95°C for 30 seconds, followed by 40 cycles of 95°C for 5 seconds and 58°C for 30 seconds. mRNA expression levels of the target genes were normalized using endogenous GAPDH and calculated based on the $2^{-\Delta\Delta C_{t}}$ method. Values were expressed as fold change relative to the control group. Experiments were performed four times for each sample.

Statistical Analysis

Statistical analysis was performed using GraphPad Prism software (GraphPad Software, San Diego). Numerical data are presented as mean ± SD unless otherwise stated. Multiple groups were analyzed by ANOVA followed by Student’s t tests for pairwise comparisons. Statistical significance was set at $p < .05$.

RESULTS

GFP-MSCs Show Typical Surface Markers and Multipotent Differentiation Capacity

The isolation and purification of bone marrow-derived MSCs is difficult due to low MSC counts (i.e., $2–5 \times 10^6$ bone marrow
nucleated cells) in mouse bone marrow, which contains large amounts of non-MSCs and hematopoietic cells [27]. Therefore, we verified the features of MSCs using standard identification procedures. MSCs isolated from mouse bone marrow exhibited the growth of colonies with spindle-shape morphology in tissue culture (Fig. 1Aa).

To verify the purity of MSCs, we analyzed cell surface markers by conventional ex vivo flow cytometry. According to the International Society for Cellular Therapy, MSCs express high levels of CD29, CD44, and Sca-1 and are negative for the endothelial, primitive hematopoietic, and leukocyte antigen markers CD31, CD34, and CD45, respectively, [28]. We observed a pattern of MSC surface marker expression that was consistent with this characterization (Fig. 1B).

We further verified the tri-lineage mesenchymal differentiation capacity of MSCs under in vitro tissue culture-differentiating conditions. After 14 days of incubation in adipogenic differentiation medium, approximately 90% of cells stained positive for Oil Red O, indicating that GFP-MSCs exhibited an adipocyte phenotype (Fig. 1Ac). Positive staining for Alizarin Red S demonstrated that GFP-MSCs were capable of osteogenic differentiation after 21 days of culture in osteogenic differentiation medium (Fig. 1Ab). Furthermore, positive staining for Toluidine Blue showed that GFP-MSCs also exhibited chondrogenic differentiation capacity (Fig. 1Ad).

**MSCs Preferentially Migrate Toward HCC Cells**

To investigate whether human HCCLM3 cells can recruit murine MSCs, we performed in vitro transwell assay to monitor the migration of bone marrow-derived MSCs toward tumor cells. We found that the number of MSCs migrating toward HCCLM3 cells was significantly higher than those in the control groups (Fig. 1C). Therefore, MSCs showed endogenous tropism to HCC cells, which have a high potential for lung metastasis.

**MSCs Have Different Homing Profiles in Healthy and Tumor Mouse Models**

Because in vivo flow cytometry can quantify changes in circulating cells over time in a noninvasive manner, we used this technique to investigate whether systemically administered MSCs show different homing profiles in healthy mice and three types of tumor mouse models with subcutaneous, orthotopically transplanted, or metastasized lung HCCLM3 cells.

The kinetics of systemically infused MSCs in healthy mice may reflect interactions between MSCs and hematopoiesis in the absence of inflammation or tumorigenic cytokines. In healthy mice, the number of GFP-MSCs steadily declined over a 24-hour period, becoming scarcely detectable in the bloodstream after 30 hours (Fig. 2A). By contrast, in mice with subcutaneous tumors, the number of GFP-MSCs initially decreased at 2 hours, increased slightly at 4 hours, and then steadily declined until becoming depleted from the bloodstream after 24 hours (Fig. 2B). After i.v. infusion, most MSCs gradually accumulate in the liver and other organs or become trapped within pulmonary capillaries [17,18]. Therefore, we examined the homing profile of MSCs in mice with HCC cells orthotopically transplanted into the liver. We found that GFP-MSCs sharply declined in number at 4 hours and became depleted from the bloodstream after 18 hours (Fig. 2C). Finally, in mice with metastasized lung tumors, the number of GFP-MSCs decreased in the first hour, increased slightly at 2 and 4 hours, and then declined sharply by 6 hours and became depleted after 16 hours (Fig. 2D). Therefore, mice with metastasized lung tumors showed the most rapid depletion of MSCs from the circulation, suggesting that MSCs preferentially home to tissue containing metastasized tumor cells.
Overall, MSCs showed shorter circulation times in tumor mouse models than in healthy mice, suggesting that exocrine factors in the cancer environment promote the localization of MSCs to tumor sites. Furthermore, circulating MSCs may preferentially migrate to tumor sites in the lungs and liver compared with subcutaneous sites.

**Verification of GFP-MSC Homing Profiles by Conventional Ex Vivo Flow Cytometry**

Conventional ex vivo flow cytometry was performed to verify the MSC homing profile measured by in vivo flow cytometry. In mice with subcutaneous tumors (Fig. 3B), orthotopic liver tumors (Fig. 3C), or metastasized lung tumors (Fig. 3D), the proportion of GFP-MSCs in the peripheral blood steadily declined over 24 hours. In healthy mice, however, the proportion of GFP-MSCs in the peripheral blood (Fig. 3A) declined at a slower rate than that in tumor-bearing mice. Therefore, in vivo and conventional ex vivo flow cytometry showed similar MSC homing profiles.

**MSCs Preferentially Migrate to Metastatic Regions**

To examine their targeting sites and biodistribution, MSCs were labeled with the carbocyanine fluorescent dye DiD [29] or EGFP. In mice with subcutaneous tumors, most MSCs migrated to the sinus space in the liver (Supporting Information Fig. S1B) and the lung parenchyma (Supporting Information Fig. S1A) as confirmed by immunofluorescence staining (Fig. 4A, 4B). MSC aggregates were trapped as emboli in the lung and liver during the first 4 hours after infusion through the tail vein (Supporting Information Fig. S2a, S2e), and, over time, smaller numbers of MSCs migrated around the vascular bed (Supporting Information Fig. S2b–S2d) and were randomly scattered across liver lobes (Supporting Information Fig. S2f–S2h). Only a few MSCs migrated to the tumor margin and engrafted to the tumor core during early stages (Fig. 4C and Supporting Information Fig. S2i, S2j). Higher number of GFP-MSCs engrafted to the subcutaneous tumor region after 12 hours (Supporting Information Fig. S2k, S2l). In mice with orthotopically transplanted liver tumors, MSCs initially engrafted to the periphery of the inoculation region and integrated into the vessel walls, whereas additional MSCs infiltrated into the liver (Supporting Information Fig. S1b) and the lung parenchyma (Supporting Information Fig. S1a) as confirmed by immunofluorescence staining (Fig. 4A, 4B).

![Figure 2](https://example.com/figure2)

**Figure 2.** The circulation times of systemically infused mesenchymal stem cells as measured by in vivo flow cytometry were shorter in tumor mouse models than in healthy mice ($n = 6$ per group). The first measurement began within 5 minutes of i.v. infusion and lasted for 2 hours continuously. Later measurements were acquired at the same vessel at 2-hour intervals until 8 hours and then 6-hour intervals until 60 hours, with each measurement lasting 1 hour. The number of detected cells per minute is shown as a function of time following infusion in (A) healthy mice, (B) mice with subcutaneous tumors, (C) mice with orthotopic liver tumors, and (D) mice with metastatic lung tumors.
HCCLM3 cells engrafted around the periphery of the alveolar capillary bed and formed metastatic nodes (Fig. 4H, 4I and Supporting Information Fig. S4a–S4d). The transplanted GFP-MSCs migrated from the vasoganglion to tumor cell accumulation areas, whereas few GFP+ cells were found in the liver lobes (Supporting Information Fig. S4e–S4h).

The percentage of grafted MSCs in the liver was highest in mice with orthotopically transplanted liver tumors and lowest in mice with metastasized lung tumors (Supporting Information Fig. S1D). Conversely, the percentage of MSCs in lung lobes was highest in mice with metastasized lung tumors and second highest in mice with orthotopic liver tumors or subcutaneous tumors. Compared with subcutaneous tumors, mice with orthotopically transplanted tumors had a measurable quantity of MSCs at the primary tumor site.

The results of H&E staining combined with immunofluorescence labeling confirmed that MSCs migrated to liver micrometastatic regions (Fig. 5A). Next, we performed in vitro cocultured transwell assay to verify whether MSCs preferentially migrated to GFP-HCCLM3 cells extracted from the orthotopically transplanted tumor site or those extracted from intrahepatic metastatic areas. In Figure 5B, the left panel shows MSCs that migrated to HCCLM3 cells extracted from the primary tumor site, whereas the right panel shows that a greater amount of MSCs migrated to tumor cells isolated from micro-metastatic foci. We found that a larger number of MSCs migrated toward cells from liver micrometastatic regions than toward cells extracted from the primary tumor site at both 12 and 24 hours (Fig. 5C). Furthermore, a significantly smaller proportion of MSCs migrated to cells from the primary tumors site than to cells from liver micrometastatic regions (Fig. 5D). These results indicate that MSCs might be more strongly recruited to HCCLM3 cells in metastatic regions than to solid tumors.

**Molecules Secreted by HCC Cells Promote the Homing of MSCs**

To investigate the interaction between MSCs and tumor cells from different regions, HCCLM3 cells were isolated from primary tumor sites or micro metastasis regions (Supporting Information Fig. S6), and cultured alone or cocultured with MSCs in a 0.4-μm transwell chamber. Total mRNA was extracted from the tumor cells to analyze the gene expression of various cytokines, chemokines, and growth factors by RT-PCR.

Considering growth factors, HCCLM3 cells from metastatic regions expressed significantly higher levels of epidermal growth factor (EGF) than HCCLM3 cells extracted from the primary tumor site (Fig. 6A and Supporting Information Fig. S5A). This effect was enhanced when HCCLM3 cells were cocultured with MSCs (Fig. 6A). The expression of platelet-derived growth factor (PDGF)-α, PDGF-β, hepatocyte growth factor (HGF), and GDF-15 increased in both the primary tumor site group and the micro metastasis group when HCCLM3 cells were cocultured with MSCs.
These results are consistent with those of previous studies showing that MSCs migrate in response to a variety of growth factors and cytokines including PDGF-α, PDGF-β, and HGF [30]. Also, coculture with MSCs stimulate HCC cells to express high amounts of GDF-15, which is a key determinant of MSC tumor tropism [31] and may promote tumorigenesis of HCC cells [32–34].

Considering chemotactic factors (Fig. 6B and Supporting Information Fig. S5B), the mRNA expression of CCL5, CXCL9, CXCL16, and CCL25 was higher in HCCLM3 cells from micrometastatic regions than in cells from primary tumor sites when cocultured with MSCs. Coculture with MSCs remarkably increased the expression of CXCL9. CXCL9 expressed by HCCLM3 cells might serve as a paracrine factor that promotes MSC recruitment and an autocrine effector that stimulates HCCLM3 invasion and metastasis [35–38]. Whether cultured alone or cocultured with MSCs, HCCLM3 cells from micrometastatic regions expressed higher levels of CCL25 than HCCLM3 cells from primary tumor sites. This result is consistent with previous findings that MSCs exhibit a chemotactic response to CCL25 [39, 40], indicating that the expression of CCL25 from micrometastatic regions might be a leading driver of MSC recruitment to tumor sites. CXCL16, CXCL9, CCL20, and CCL25 have also been found to induce migration of MSCs in a dose-dependent manner [41]. In addition, elevated expression of CXCL16 by prostate cancer cells and breast cancer cells also promotes MSC recruitment [8,42,43].

Considering matrix metalloproteinases (MMPs), HCCLM3 cells from metastatic regions showed higher expression of MMP9 than cells from the primary tumor site (Supporting Information Fig. S5C). HCCLM3 cells cocultured with MSCs showed higher expression of MMP1, MMP3, and MMP9 than GFP-HCCLM3 cells cultured alone (Fig. 6C). These increased levels of MMPs might recruit MSC migration to tumor sites, as MMP1 has been found to mediate MSC tumor tropism through crosstalk with the SDF-1/CXCR4 axis [44].

Considering inflammatory cytokines, higher levels of interleukin (IL)1-β, IL2, and IL7 expression were found in HCCLM3 cocultured with MSCs than in HCCLM3 cells cultured alone (Fig. 6C). IL1-β is an inflammatory cytokine that upregulates the production of MMPs, which stimulates the chemotactic migration of MSCs through the extracellular matrix [45,46]. Elevated expression of inflammatory cytokines stimulated by coculture with MSCs might also enhance the metastasis of HCC cells [47–49].
In conclusion, GFP-HCCLM3 cells may recruit MSCs by expressing various cytokines that enhance migration, and MSCs may exert direct paracrine influences on tumor cells, thereby promoting cancer angiogenesis, invasion, and metastasis.

**DISCUSSION**

In this study, we investigated the dynamic homing profiles of systemically infused MSCs in healthy mice and three types of conditions.
tumor mouse models. We use MSCs isolated from murine bone marrow, which is considered a highly heterogeneous population in terms of cell size and surface marker expression. Several studies show that MSCs migrate to sites of injury, ischemia, and tumors by a variety of mechanisms, thus their homing efficiency after systemic infusion could be affected by many different factors. For example, MSCs trapped in mouse lungs after i.v. infusion must overcome major obstacles to exert a therapeutic effect [14,50,51]. The factors that affect whether MSCs predominately become passively entrapped in small diameter blood vessels or are actively recruited to tumor microenvironments need to be further investigated.

In vivo flow cytometry can be used to quantitatively detect fluorescence-labeled cells in the circulation in a noninvasive manner. Here, we used this technique to monitor the trafficking and homing profiles of systemically infused MSCs under physiological and pathological states. We found that in mice with subcutaneous tumors, MSCs were completely depleted from the peripheral blood after 24 hours, whereas MSC depletion required 30 hours in healthy mice. In mice with orthotopically transplanted liver tumors, most MSCs were depleted from the bloodstream as early as 4 hours, with complete depletion after 18 hours. However, mice with metastasized lung tumors showed the fastest clearance of MSCs, with complete depletion after 12 hours. Based on these findings, we speculate that the homing of MSCs depends not only on passive entrapment but also on active engraftment to neoplastic tissue. If most MSCs are passively arrested in capillaries or microvessels, circulation times should be similar between physiological and pathological states. Rather, the observed variation in clearance kinetics between tumor mouse models suggests that different paracrine factors released from HCC cells in different tumor sites affect their recruitment abilities. MSC trafficking from the bloodstream to tissues and organs occurs in two stages. In the first stage, MSCs may adhere to or transmigrate from the vasculature depending on the blood supply of the target tissue and the specific cytokines in the peripheral blood. In the second stage, after leaving the circulation, specific cytokines promote MSC engraftment to tumor sites or precancerous lesion areas but not to normal tissue parenchyma. This may explain why MSCs exhibited the longest homing times in mice with subcutaneous tumors, which have poorer blood supply compared with mice with liver or lung tumors. By contrast, mice with metastasized lung tumors exhibited the fastest clearance of MSCs from peripheral blood vessels, which may be due to the combined effect of passive and active homing mechanisms.

MSCs may exhibit an endogenous tendency to engraft to tumors and become part of the tumor microenvironment. In mice with orthotopic liver tumors, MSCs preferentially accumulated at intrahepatic metastatic regions instead of the primary tumor site. Thus, we speculate that MSCs show different patterns of responses to paracrine factors secreted from primary tumor sites and metastatic regions both in vitro and in vivo. By analyzing gene expression, we found that various cytokines were highly expressed when HCC cells were cocultured with MSCs versus cultured alone, which might lead to differences in the homing of MSCs to primary and metastatic regions. In addition, by releasing multiple cytokines into the bloodstream, tumor cells can specifically promote MSC migration [52]. On the other hand, MSCs can promote the malignant transformation of tumor cells through soluble factors [8], cell-cell interactions [7,43], alterations of the extracellular matrix [4,53,54], or constitute an early protective niche for the residence of cancer-propagating cells [55]. The observation that MSCs preferentially home to micrometastatic regions suggests that MSCs could potentially serve as a bio-detector to predict tumorigenesis and tumor development [56].

Based on their inherent tumor-trophic migratory properties, MSCs are promising anti-cancer agents that could be used to treat different cancer types [57]. After exogenous gene transfection, MSCs can home to tumor sites and express reporter genes that exert targeted anticancer effects. MSCs have been genetically modified to express ILS [58,59], interferons [60–62], prodrugs [63,64], oncolytic viruses [65–67], and pro-apoptotic proteins [68,69]. Although some studies provide conflicting data...
on the trafficking efficiency of systematically infused MSCs to tumor sites, converging evidence indicates that MSCs can produce therapeutic effects by secreting desirable anticancer agents into the bloodstream, either when they become entrapped in nontarget locations or after their engraftment to tumor sites [15]. Recently, MSCs have been explored as cell-based vehicles for delivering therapeutic agents, such as nanoparticles, for targeted tumor therapy [70–72]. However, a number of studies suggest that MSCs are recruited by neoplasia as a source of cancer-associated fibroblastic cells, creating a favorable niche that promotes carcinogenic progression by secreting paracrine factors, facilitating epithelial–mesenchymal transition, and increasing metastatic abilities. Because it might be risky to administer exogenous MSCs as drug carriers for long periods of time in tumor environments, it is important to understand MSCs homing profiles and determine appropriate therapeutic time window. We need to know the circulation time of MSCs as vehicles for delivering therapeutic agent to target regions, while avoiding the participation of MSCs in tumor progression. One good approach might be to kill MSCs via suicide gene or therapeutic agents after MSCs home to tumor microenvironment and release drugs. Therefore, an understanding of differences in the homing kinetics of MSCs to tumor sites and the kinetics of drug release from MSCs is important for avoiding systemic side effects. Furthermore, understanding the circulation times of MSCs is necessary for studying the relationship between loading dosages and the pharmacodynamics of MSC-released agents. For MSC-encapsulated nanoparticles containing chemotherapeutic or cytotoxic agents, an appropriate drug loading capacity may be critical for preventing the death of MSCs in the circulation and the loss of their tropic properties before homing to tumor sites.

Moreover, whether endogenous bone marrow derived MSCs mobilize into the bloodstream during healthy and diseased state and target to specific tissues needs to be investigated. Our work may provide insights into the homing profiles of endogenous bone marrow derived MSCs both in physiological and pathological condition by using in vivo flow cytometry.

**REFERENCES**

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
2. Schäfer M, Werner S. Cancer as an overwhelming wound: An old hypothesis revisited. Nat Rev Mol Cell Biol 2008;9:628–638.
3. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol Mech Dis 2006;1:119–150.
4. Quante M, Tu SP, Tomita H et al. Bone marrow–derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011;19:257–272.
5. Ezer N, Truitt M, Olson P et al. Cancer–associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kB–dependent manner. Cancer Cell 2010;17:135–147.
6. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 2010;12:87–117.
7. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557–563.
8. Jung Y, Kim JK, Shiozawa Y et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 2013;4:1795.
9. Bexell D, Gunnarsson S, Tormin A et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte–like migratory vehicles in experimental gliomas. Mol Ther 2009;11:1189–1197.
10. Sasportas LS, Kasmiieh R, Wakimoto H et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009;106:4822–4827.
11. Loedinginger MR, Edlaoudi A, Davies D et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009;69:4134–4142.
12. Nakamura K, Ito Y, Kawano Y et al. Anti-tumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11:1155–1164.
13. Studeny M, Marinì FC, Dembinski JL et al. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593–1603.
14. Bexell D, Gunnarsson S, Tormin A et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte–like migratory vehicles in experimental gliomas. Mol Ther 2009;17:183–190.
15. Lee RH, Pulin AA, Seo MJ et al. Intravenous MSCs improve myocardial infarction in mice because cells emobilized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009;5:34–63.
16. Harting MT, Jimenez F, Xue H et al. Intravenous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg 2009;110:1189–1197.
17. Kidd S, Spaeth E, Dembinski JL et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009;27:2614–2623.

**DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

The authors indicate no potential conflicts of interest.
18 Gao J, Dennis JE, Muzic RF et al. The Dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2003;169:12–20.

19 Loebinger MR, Kytotatos PG, Turmaine M et al. Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res 2009;69:8862–8867.

20 Novak J, Georgioukoni I, Wei X et al. In vivo flow cytometer for real-time detection and quantification of circulating cells. Opt Lett 2004;29:77–79.

21 Fan Z-C, Yan J, Liu G-D et al. Real-Time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic model by in vivo flow cytometry assesses resection on metastasis. Cancer Res 2012;72:2683–2691.

22 He W, Wang H, Hartmann LC et al. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. PNAS Natl Acad Sci USA 2007;104:11760–11765.

23 Sipkins DA, Wei X, Wu JW et al. In vivo imaging of specialized bone marrow endothelial micromounters for tumour engraftment. Nature 2005;435:960–973.

24 Fan Z, Spencer JA, Lu Y et al. In vivo tracking of color-coded effector, natural and induced regulatory T cells in the allograft response. Nat Med 2010;16:718–722.

25 Wei X, Sipkins DA, Pitsillides CM et al. Real-time detection of circulating apoptotic cells by in vivo flow cytometry. Mol Imaging 2005;4:415–416.

26 Li Y, Tang Z, Ye S et al. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 2003;129:43–51.

27 Sun S, Guo Z, Xiao X et al. Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells 2003;21:527–535.

28 Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315–317.

29 Teo GS, Yang Z, Carman CV et al. Intravital imaging of mesenchymal stem cell trafficking and association with platelets and neutrophils. Stem Cells 2015;33:265–277.

30 Baek SJ, Kang SK, Ra JC. In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Exp Mol Med 2011;43:596–603.

31 Lourenco S, Teixeira VM, Kolber Y et al. Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. J Immunol 2015;194:3463–3474.

32 Brown DA, Lindmark F, Stattin P et al. Marrow stromal cell cytokine-1: A new prognostic marker in prostate cancer. Clin Cancer Res 2009;15:6658–6664.

33 Corre J, Labat E, Espagnolle N et al. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res 2012;72:1395–1406.

34 Bruzzeze F, Hagglof C, Leonida A et al. Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15. Cancer Res 2014;74:3048–3047.

35 Liu H, Pan Z, Li A et al. Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol 2008;5:373–378.

36 Capone F, Costantini S, Guerriero E et al. Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw 2010;21:99–104.

37 Ling CC, Ng KT, Shao Y et al. Post-transplant endothelial progenitor cell mobilization via CCL10/CXCR3 signaling promotes liver tumor growth. J Hepatol 2014;60:103–109.

38 Mir MA, Maurer MU, Zisemare SC et al. Elevated serum levels of IL-2R, IL-1RA, and CCL9 are associated with a poor prognosis in follicular lymphoma. Blood 2015;125:992–998.

39 Binger T, Stich S, Andreas K et al. Migration potential and gene expression profile of human mesenchymal stem cells induced by CCL25. Exp Cell Res 2009;315:1468–1479.

40 Ren G, Zhao X, Wang Y et al. CC02-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell 2012;11:812–824.

41 Chamberlain G, Wright K, Rot A et al. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: Comparison with human. PLoS One 2008;3:2934–2940.

42 Carpentier A, Tesfaye A, Chu V et al. Engrafted human stem cell–derived hepatocytes establish an infectious HCV murine model. J Clin Invest 2014;124:4953–4964.

43 Chaturvedi P,Gilkes DM, Wong CCL. Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest 2013;123:189–205.

44 Reigan MR, Ghobrial IM. Multiple myeloma mesenchymal stem cells: Characterization, origin, and tumor-promoting effects. Clin Cancer Res 2012;18:342–349.

45 Duan CW, Shi J, Chen J et al. Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell. 2014;25:778–793.

46 Ren G, Chen X, Dong F et al. Concise review: Mesenchymal stem cells and translational medicine: Emerging issues. STEM CELLS TRANSKL MOL 2012;5:1–58.

47 Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012;64:739–748.

48 Gao P, Ding Q, Wu Z et al. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 2010;290:157–166.

49 See SH, Kim KS, Park SH et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 2011;18:488–495.

50 Nakamizo A, Marini F, Amato P et al. Human bone marrow–derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307–3318.

51 Ren C, Kumar S, Chanda D et al. Therapeutic potential of mesenchymal stem cells producing interferon-α melanoma lung metastasis model. STEM CELLS 2008;26:2332–2338.

52 Ren C, Kumar S, Chanda D et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis model. Cancer Res 2008;15:1446–1453.

53 Danks MK, Yoon KJ, Bush RA et al. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 2007;67:22–25.

54 Cavarretta IT, Altanerova V, Matuskova M et al. Adipose tissue–derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther 2010;18:223–231.

55 Aghi M, Martuza RL. Oncolytic viral therapies—the clinical experience. Oncogene 2005;24:7802–7816.

56 Konarova S, Kawakami Y, Stoff-Khalili MA et al. Mesenchymal progenitor cells as cellular...
vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006;5:755–766.

67 Sonabend AM, Ulasov IV, Tyler MA et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. STEM CELLS 2008;26:831–841.

68 Sasportas LS, Kasmeh R, Wakimoto H et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009;106:4822–4827.

69 Loebinger MR, Eddaoudi A, Davies D et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009;69:4134–4142.

70 Gao Y, Wang Y, Fu A et al. Tracking mesenchymal stem cell tumor-homing using fluorescent silica nanoparticles. J Mater Chem B 2015;3:1245–1253.

71 Cheng H, Kastrup CJ, Ramanathan R et al. Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. ACS Nano 2010;4:625–631.

72 Hwang BW, Kim SJ, Park KM et al. Genetically engineered mesenchymal stem cell therapy using self-assembling supramolecular hydrogels. J Control Release 2015;220:119–129.

See www.StemCellsTM.com for supporting information available online.